OBiO Pharmaceutical

OBiO Technology is a leading contract development and manufacturing organization (CDMO) specializing in the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector discovery, process development, and large-scale GMP manufacturing for clinical and commercial use. Their expertise covers a broad range of viral vectors, including AAV, lentivirus, adenovirus, and oncolytic viruses, as well as non-viral modalities like mRNA and plasmid DNA. With its state-of-the-art 'OBiO Intelli-M' manufacturing base in Shanghai, the company supports global biotechnology and pharmaceutical clients in accelerating the transition of innovative therapies from research to market. OBiO is publicly listed on the Shanghai Stock Exchange STAR Market and is recognized for its high-quality bioprocessing capabilities.